Sclerotherapy Market By Product Type (Sclerosants {Detergents, Osmotic Agents, Chemical Irritants},  Medical Devices {Needles and Syringes, Vein Visualization Devices, Compression Garments}), By Treatment Type (Liquid Sclerotherapy, Foam Sclerotherapy, Ultrasound-Guided Sclerotherapy), By Application (Varicose Veins, Spider Veins), and By End User (Hospitals, Ambulatory Surgical Centers, Dermatology Clinics, Specialized Vein Clinics), Region & leading company profiles, Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Sclerotherapy market accounted for USD 1.27 Billion in 2024 and is expected to reach USD 2.24 Billion by 2035, growing at a CAGR of around 5.3% between 2025 and 2035. The sclerotherapy market consists of a minimally invasive medical procedure that is used for treating varicose veins, spider veins, and other venous disorders. The treatment works by injecting a sclerosant solution or foam into the affected veins, making them collapse and be absorbed by the body, thus enhancing vascular health and cosmetic appearance.

Applications include cosmetic vein treatment and management of venous disorders. The market includes sclerosants such as liquid and foam, syringes, needles, and devices. Growth is propelled by an aging population, sedentary lifestyles, and increased demand for non-invasive procedures. North America leads due to advanced healthcare infrastructure, but Asia-Pacific is the fastest-growing region due to increasing awareness and investment in healthcare. The outlook for the market is further enhanced by innovation in foam sclerosants and ultrasound-guided delivery systems.

Report Scope:

Market Dynamics

Increasing cases of varicose and spider veins driving treatment demand.

The rising incidence of varicose and spider veins is a key factor explaining the sclerotherapy market. Varicosis mainly affects women and occurs in older women at a far higher rate than in men. However, spider veins may occur in over 50% of all women. The growing number of elderly persons, population inactivity, and rising obesity rates are some of the causes contributing to this increased occurrence. This indicates that the need for venous problems like sclerotherapy is increasing as more people develop them. Patients and doctors choose sclerosing because it is a minimally invasive procedure that can eliminate symptoms and make damaged veins recover. In a similar vein, the growth in the patient base particularly helps the sclerotherapy market.

Higher preference for minimally invasive, non-surgical vein treatment solutions.

Underlying trends for the sclerotherapy market include the shift towards "less invasive and non-surgical vein therapies." Sclerotherapy is chosen by patients more and more often instead of surgical interventions because the recovery period takes less time, the complications that can happen are less severe, and the therapeutic effect results in a better appearance.

Noninvasive management techniques also correlate with contemporary top prioritization of the patient’s comfort and coziness. This transition is especially obvious with varicose and spider veins, where sclerotherapy accomplishes the procedures with very little recovery period. The Society for Vascular Surgery (SVS) estimates that, in the United States, "20-25 million" people look for noninvasive treatments for varicose veins. The increasing use of such alternatives owing to enhancement in sclerosants and delivery systems will further propel the use of sclerotherapy internationally.

Elevated treatment costs limit access for price-sensitive patients.

Rising costs also remain a major issue in the sclerotherapy market as it limits the access of patients to get the treatment, as you have seen with new economies or with underinsured populations. The high cost of advanced sclerosants and corresponding devices, as well as adherence to the methods, may be indicative of the fact that this procedure is not affordable for middle- or low-income populations.

Insurance services do not cover all costs of such procedures, and, more specifically, they do not offer insurance for beauty treatments, such as the removal of spider veins. This is particularly the case in rural and underdeveloped areas where the cost of the product plays a significant role in its definition. This restraint will call for affordable solutions, awareness, and improved insurance coverage to increase market access and growth.

Improved sclerosant formulations offer safer and more effective vein treatments.

Newer generations of sclerosants” offer a great chance for the development of the sclerotherapy market due to the better safety and effectiveness of vein treatments. Enhancements of the formulations, like the foam sclerosants, lead to the coverage of vein space, better control, and fewer adverse effects, which makes various procedures more effective and less risky.

These innovations work across a broader spectrum of cases: where veins are larger or more complicated something that was not easy to address before. Improved formulations also decrease pain to the patient and minimize the time taken for a patient to recover, thus increasing demand for sclerotherapy as compared to surgical procedures. Moreover, novel sclerosants with fewer side effects increase physician and consumer confidence, consequently resulting in increased use. This continuity of innovation fits the increasing realization of more efficient and friendlier treatments for patients in the medical and beauty domains.

Rising adoption of sclerotherapy procedures in developing healthcare markets.

The incremental demand for sclerotherapy processes across emerging healthcare markets is anticipated to open new avenues for the sclerotherapy market. The economies of developing countries in the Asia-Pacific, Latin America, and the Middle East have seen progress in the healthcare front and growing awareness of venous health.

This is forcing patients to choose non-surgical treatments like sclerotherapy. Also, the middle population is increasing with more disposable income, and they are looking for improved medical and aesthetic services. These value propositions address the regions of interest by lowering the cost of the solutions and raising patient and caregiver knowledge. Because healthcare services are becoming more affordable and accessible, sclerotherapy has a very high growth potential.

Industry Experts Opinion

"Sclerotherapy remains one of the most effective treatments for varicose and spider veins. This minimally invasive procedure involves injecting a solution directly into the vein, causing it to collapse and fade over time. Advances in sclerotherapy, including the use of foam sclerosants, have enhanced the precision and outcomes, making it an ideal treatment for both cosmetic concerns and medical conditions related to vein health."

• Dr. Margaret Greene, Vascular Surgeon and Sclerotherapy Specialist

Segment Analysis

Based on the product type, the sclerotherapy market is classified into sclerosing agents and medical devices. The most active segment of the sclerotherapy market is sclerosing agents, particularly detergents and chemical irritants. The veins are varicose and spider veins that are effectively cured by them because they work by making the veins collapse and then disappear. Detergents are the most important among them, and they have become so famous for their unique properties of hitting the larger veins without unwanted complications.

Treatments, including the least invasive procedures that use them for speedy recovery, control the market for sclerotherapy. Since sclerosants constitute the main component of treatment, their success in minimally invasive treatments has caused the market to grow rapidly, making them an essential component of the sclerotherapy process. Due to their high effectiveness, these goods play a significant role in this market by providing reduced health care expenses. They are also successful in both medical applications.

Based on the Treatment Type, the Sclerotherapy market is classified into Liquid Sclerotherapy, Foam Sclerotherapy, and Ultrasound-Guided Sclerotherapy. Spider and varicose veins can be effectively treated with liquid sclerotherapy. This is the most popular method because of its simplicity and success. It is also by far the cheapest method. These injected liquid substances cause the vein to disappear and contract appropriately.

The laser heat emitted into the vein damages it and thus deprives it of the fitting needed to be removed. It has been popular for so long that 90% of all foam treatments have not even been done by anyone else. The treatment period is one of the most important factors that should be used in considering the treatment procedure for varicose veins.

Regional Analysis

The North American sclerotherapy market is mainly growing due to the rising awareness of varicose veins and various treatments offered in the region that has a well-developed healthcare system. The need for varicose vein treatment is increasing because sclerotherapy is less painful and causes faster recovery than surgical intervention. The availability of some vital healthcare infrastructure and competent physicians in the U.S. and Canada also helps the growth of the market.

Also, increasing preference for sclerotherapy in cosmetic surgeries propels market growth. The market progress is also being affected by regulatory approvals and developments in injection techniques. In addition, a continually growing population of people in North America is another issue, as sclerotherapy is often done in the case of varicose veins in elderly people. Greater insurance reimbursement for varicose vein treatment raises the availability of sclerotherapy.

The sclerotherapy market in the Asia Pacific region is dynamically growing due to the rising number of varicose veins and venous insufficiency diseases. Developed nations such as Japan, China, and India have reported an increased usage ratio of sclerotherapy due to improving health consciousness among patients and an increasing trend of outpatient procedures. This is so because there are cheaper treatment methods, insurance policies, and technological improvements to less invasive procedures.

The availability of regulatory support for new treatment innovations and the enhancement of the healthcare infrastructure are also boosting the market. Also, a move from public to private facilities, especially in urban settings, has pushed the sclerotherapy rates high. A rising consciousness level regarding aesthetic issues among the people also helps to provide a boost to the market in this region.

Competitive Landscape

The competition in the sclerotherapy market is intense, as a large number of well-established players in the medical devices industry and the pharmaceutical sector are involved. Some of the leading companies in the market include Boston Scientific, Medtronic, Abbott Laboratory, and others that offer a diverse portfolio of sclerotherapy equipment and medicament, including innovative injectable sclerotherapy solutions and multipurpose devices.

Many firms, including AngioDynamics and Stryker Corporation, work on upgrading minimally invasive technologies for better treatment consequences and patient satisfaction. Moreover, Mylan N.V. and Chemische Fabrik Kreussler are the providers of sclerosing agents, as the market is in constant need of non-invasive vein therapy. New entrants such as Meditek Systems and Applied Biomedical are also shifting more, concentrating more on the expansion of their portfolio. Joint ventures and affiliations are also on the rise as firms seek to spread their base and extend their markets.

Sclerotherapy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2023, “Viatris Inc.” and “Mapi Pharma Ltd.” announced that the U.S. FDA accepted their New Drug Application (NDA) for “GA Depot”, a long-acting glatiramer acetate formulation developed for treating relapsing multiple sclerosis (MS).
• In July 2024, “Swizton MMedicare partnered with “Medtronic” to establish India’s first specialized clinic for varicose vein treatment. This initiative aims to improve patient care by offering advanced diagnostic and therapeutic solutions for venous diseases.

Report Coverage:

By Product Type

• Sclerosants
  • Detergents
  • Osmotic Agents
  • Chemical Irritants
• Medical Devices
  • Needles and Syringes
  • Vein Visualization Devices
  • Compression Garments

By Treatment Type

• Liquid Sclerotherapy
• Foam Sclerotherapy
• Ultrasound-Guided Sclerotherapy

By Application

• Varicose Veins
• Spider Veins

By End User

• Hospitals
• Ambulatory Surgical Centers
• Dermatology Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Boston Scientific Corporation
• Chemische Fabrik Kreussler & Co. GmbH
• LGM Pharma
• Troikaa Pharmaceuticals Ltd.
• TIANYU CHANG’AN GROUP
• Mylan N.V.
• AngioDynamics
• Meditek Systems Pvt. Ltd.
• Medtronic
• Medical Devices Business Services, Inc.
• Stryker Corporation
• Smith & Nephew
• Abbott Laboratories
• Applied Biomedical, LLC
• MTW Endoskopie Manufaktur
• Cook Medical
• Air-Tite Products Co., Inc.
• Metro Vein Centers

Frequently Asked Questions (FAQs)